- Klava Innovation is integrating its digital therapy Quitoxil® into the home care services of Isis Medical
- The partnership targets patients with chronic respiratory conditions.
- An initial deployment phase has begun within the Isis Medical network, particularly in the Languedoc-Roussillon region.
A strategic partnership focused on smoking cessation
Klava Innovation, a Nice-based medtech company specializing in digital therapies, has partnered with Isis Medical, a leading player in home healthcare, to integrate its Quitoxil® solution into care pathways for patients suffering from chronic respiratory diseases.
This partnership strengthens smoking cessation support as part of a secondary prevention approach, leveraging Isis Medical’s territorial network — more than 50 branches — and the advanced capabilities of Quitoxil®, which combines cognitive therapy, motivational coaching, and artificial intelligence.
An initial operational phase has been launched in the Languedoc-Roussillon region.
This collaboration contributes to transforming home care practices by placing smoking cessation at the heart of monitoring for patients with COPD or sleep apnea.
By integrating Quitoxil® into the field teams’ monitoring tools, Isis Medical is expanding its service offering, coordinating with both hospital-based and private healthcare professionals.
For its part, Klava Innovation is extending its model beyond the pharmacy network while maintaining a point of access through pharmacies and their online shops, thus consolidating its strategy of integration into localized healthcare pathways. The partnership is built on a shared vision: combining prevention, proximity, and digital tools to provide care tailored to clinical realities.
Klava Innovation: a Nice-based success story in digital therapies
Based in Nice, Klava Innovation is emerging as a rising name in the French medtech sector. Its Quitoxil® solution, the first digital smoking cessation therapy available in pharmacies, marks a significant step forward in addiction treatment.
The application uses artificial intelligence to deliver a personalized cessation pathway, combining cognitive-behavioral therapy, motivational coaching, stress management, and support from peer helpers trained in addiction medicine.
In March 2024, Klava raised €1 million with the support of Angel’s Bay Invest to accelerate the deployment of Quitoxil® in pharmacies and train pharmacists in its use.
With strong local roots and a commercial presence in Paris, the company benefits fully from the innovative ecosystem of the Nice Côte d’Azur Metropolis, which has supported its rapid growth since its creation in 2021 by Alexia Adda, Didier Adda, and Dr Ivan Gasman.
The vitality of the healthcare sector on the Nice Côte d’Azur
The region’s appeal in healthcare is based on a structured ecosystem combining cutting-edge infrastructure, academic excellence, and entrepreneurial drive.
The Nice University Hospital (CHU), in partnership with Université Côte d’Azur, is leading major projects such as the IHU RespirERA, dedicated to chronic respiratory diseases. Selected in 2023 under the France 2030 program, this university hospital institute is one of 12 projects chosen nationwide from more than 90 applications, confirming Nice’s strategic positioning in precision medicine and technological innovation.
This ecosystem also includes the Skin Institute, focused on digital dermatology, and 3IA Côte d’Azur, which develops AI applications in healthcare, such as biomarkers, digital twins, and predictive medicine.
Université Côte d’Azur plays a central role in this dynamic, notably through the Nucleate France UniCA program, which supports PhD students’ transition to entrepreneurship in the life sciences. In parallel, the future spin-off Dimicare, originating from UniCA, INSERM, and CNRS, is developing a new class of targeted antibiotics identified using the ARROW screening platform.
This scientific momentum is also driven by a network of innovative startups such as Algenscribe (genomic medicine), Roca Therapeutics (biotechnology), ExAdEx-Innov (adipose tissue-based therapies), and Klava Innovation (smart medical devices).
The entire sector benefits from strong structural support through Eurobiomed, the interregional competitiveness cluster, and from extensive international outreach, reinforced by strategic partnerships, notably with Beirut.
